Apalutamide Plus ADT Leads to Survival Benefit in mCSPC
Neeraj Agarwal, MD, discusses the results from the randomized phase III TITAN trial, which enrolled over 1,000 patients with newly diagnosed metastatic castration-sensitive prostate cancer and randomized them to either androgen deprivation therapy plus the novel androgen receptor inhibitor apalutamide or ADT alone.
Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses the results from the randomized phase III TITAN trial, which enrolled over 1,000 patients with newly diagnosed metastatic castration-sensitive prostate cancer and randomized them to either androgen deprivation therapy (ADT) plus the novel androgen receptor inhibitor apalutamide (Erleada) or ADT alone.
The study included 2 coprimary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS). The apalutamide combination was superior to ADT alone for both endpoints, Agarwal says. There was a 52% reduction in the risk of radiographic disease progression and a 37% reduction in the risk of death. There was also an impressive improvement in OS, Agarwal notes
The results from the TITAN trial ultimately led to theFDA’s approval of apalutamide for patients with metastatic castration-sensitive prostate cancer
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
